Table 1 Patient characteristics in the present cohort
All patients (n = 5576) | Edaravone group (n = 3825) | Non-edaravone group (n = 1751) | P valuea | |
|---|---|---|---|---|
Age, years | 79 [73, 85] | 78 [72, 84] | 80 [74, 87] | < 0.001 |
Male, n (%) | 3,154(56.6) | 2,149(56.2) | 1,005 (57.4) | 0.396 |
BMI, kg/m2 | 22.5 [20.2, 24.9] | 22.6 [20.4, 25.0] | 22.5 [20.0, 24.8] | 0.095 |
BMI < 20, n (%) | 1,133/5,200 (21.8) | 734/3,553 (20.7) | 399/1,647 (24.2) | 0.004 |
JCS at admission, n (%) | 0.001 | |||
0 | 2,737 (49.1) | 1,812 (47.4) | 925 (52.8) | |
1–3 | 2,264 (40.6) | 1,602 (41.9) | 662 (37.8) | |
10–30 | 445 (8.0) | 324 (8.5) | 121 (6.9) | |
100–300 | 130 (2.3) | 87 (2.3) | 43 (2.5) | |
mRS 0–2 before stroke, n (%) | 4,163 (74.7) | 2,945 (78.0) | 1,218 (69.6) | < 0.001 |
BI at admission, points | 30 [0, 70] | 25 [0, 65] | 35 [0, 75] | < 0.001 |
BI at admission ≥ 90, n (%) | 1,070 (19.2) | 713(18.6) | 357 (20.4) | 0.124 |
eGFR, mL/min /1.73m2 | 63.2 [50.2, 77.3] | 66.5[55.4, 79.8] | 54.0 [37.4, 70.0] | < 0.001 |
eGFR < 60, n (%) | 1,813/4,208 (43.1) | 1,000/2,831 (35.3) | 813/1,377 (59.0) | < 0.001 |
BUN/Cr ratio | 20.8 [16.6, 26.0] | 21.3 [17.0, 26.3] | 19.6 [15.8, 25.1] | < 0.001 |
Mediation at onset, n (%) | ||||
DM medication | 657 (11.8) | 399 (10.4) | 258 (14.7) | < 0.001 |
HTN medication | 1,560 (28.0) | 1,020 (26.7) | 540 (30.8) | 0.001 |
HL medication | 1,266 (22.7) | 864 (22.6) | 402 (23.0) | 0.759 |
Oral antiplatelet | 1,812 (32.5) | 1,251 (32.7) | 561 (32.0) | 0.622 |
Intravenous drug use after onset, n (%) | ||||
Alteplase | 56 (1.0) | 48 (1.3) | 8 (0.5) | 0.006 |
Argatroban | 670 (12.0) | 514 (13.4) | 156 (8.9) | < 0.001 |
Ozagrel | 4 (0.1) | 0 (0) | 4 (0.2) | 0.003 |